

## MLH1-methylated endometrial cancer under 60 years of age as the “sentinel” cancer in female carriers of high-risk constitutional MLH1 epimutation

Megan P. Hitchins<sup>a,1,b,\*</sup>, Rocio Alvarez<sup>a</sup>, Lisa Zhou<sup>a</sup>, Francesca Aguirre<sup>a</sup>, Estela Dámaso<sup>b,c,d,1</sup>, Marta Pineda<sup>d,e</sup>, Gabriel Capella<sup>d,e</sup>, Justin J.-L. Wong<sup>f</sup>, Xiaopu Yuan<sup>g</sup>, Shawna R. Ryan<sup>h</sup>, Devika S. Sathe<sup>i</sup>, Melanie D. Baxter<sup>j</sup>, Timothy Cannon<sup>k</sup>, Rakesh Biswas<sup>k</sup>, Tiffani DeMarco<sup>k</sup>, Doreen Grzelak<sup>l</sup>, Heather Hampel<sup>m,n,1,2</sup>, Rachel Pearlman<sup>m,2</sup>

<sup>a</sup> Department of Biomedical Sciences, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA, USA

<sup>b</sup> Department of Medicine (Oncology), Stanford University, Stanford, CA, USA

<sup>c</sup> Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, Av. Gran Via de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain

<sup>d</sup> Molecular Genetics Unit, Elche University Hospital, Elche, Alicante. Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), FISABIO- Elche Health Department, Spain

<sup>e</sup> Consortium for Biomedical Research in Cancer – CIBERONC, Carlos III Institute of Health, Av. De Monforte de Lemos 5, 28029 Madrid, Spain

<sup>f</sup> Epigenetics and RNA Biology Program Centenary Institute, and Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales 2050, Australia

<sup>g</sup> Department of Pathology and Laboratory Medicine, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA, USA

<sup>h</sup> Hereditary Cancer Assessment Program, University of New Mexico Comprehensive Cancer Center, NM, USA

<sup>i</sup> Precision Medicine and Genetics, Frederick Health, MD, USA

<sup>j</sup> Saint Francis Healthcare System, Cape Girardeau, MO, USA

<sup>k</sup> Cancer Genetics Program, Inova Schar Cancer Institute, Inova Fairfax Hospital, VA, USA

<sup>l</sup> Virginia Cancer Specialists, Fairfax, VA, USA

<sup>m</sup> Department of Internal Medicine and the Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA

<sup>n</sup> Division of Clinical Cancer Genomics, Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA

### HIGHLIGHTS

- High-risk constitutional *MLH1* methylation underlies a significant proportion of early-onset EC with tumor *MLH1* methylation.
- EC with tumor *MLH1* methylation is sometimes the ‘sentinel’ cancer in women with constitutional *MLH1* methylation.
- Low-level mosaic constitutional *MLH1* methylation confers high-risk for *MLH1*-methylated cancers including EC.
- Constitutional *MLH1* methylation testing is warranted in cases with early-onset, or prior history of, *MLH1*-methylated cancer.

### ARTICLE INFO

#### Article history:

Received 5 January 2023

Received in revised form 22 February 2023

Accepted 26 February 2023

Available online 8 March 2023

#### Keywords:

Endometrial cancer

*MLH1* methylation

Constitutional *MLH1* epimutation

Lynch syndrome

### ABSTRACT

**Objective.** Universal screening of endometrial carcinoma (EC) for mismatch repair deficiency (MMRd) and Lynch syndrome uses presence of *MLH1* methylation to omit common sporadic cases from follow-up germline testing. However, this overlooks rare cases with high-risk constitutional *MLH1* methylation (epimutation), a poorly-recognized mechanism that predisposes to Lynch-type cancers with *MLH1* methylation. We aimed to determine the role and frequency of constitutional *MLH1* methylation among EC cases with MMRd, *MLH1*-methylated tumors.

**Methods.** We screened blood for constitutional *MLH1* methylation using pyrosequencing and real-time methylation-specific PCR in patients with MMRd, *MLH1*-methylated EC ascertained from (i) cancer clinics ( $n = 4$ , <60 years), and (ii) two population-based cohorts; “Columbus-area” ( $n = 68$ , all ages) and “Ohio Colorectal Cancer Prevention Initiative (OCCPI)” ( $n = 24$ , <60 years).

\* Corresponding author at: Cedars-Sinai Medical Center, 1800 Beverley Blvd, Los Angeles, CA 90048, USA.

E-mail address: [megan.hitchins@cshs.org](mailto:megan.hitchins@cshs.org) (M.P. Hitchins).

<sup>1</sup> Current affiliation.

<sup>2</sup> Equal contributions.

**Results.** Constitutional *MLH1* methylation was identified in three out of four patients diagnosed between 36 and 59 years from cancer clinics. Two had mono-/hemiallelic epimutation (~50% alleles methylated). One with multiple primaries had low-level mosaicism in normal tissues and somatic “second-hits” affecting the unmethylated allele in all tumors, demonstrating causation. In the population-based cohorts, all 68 cases from the Columbus-area cohort were negative and low-level mosaic constitutional *MLH1* methylation was identified in one patient aged 36 years out of 24 from the OCCPI cohort, representing one of six (~17%) patients <50 years and one of 45 patients (~2%) <60 years in the combined cohorts. EC was the first/dual-first cancer in three patients with underlying constitutional *MLH1* methylation.

**Conclusions.** A correct diagnosis at first presentation of cancer is important as it will significantly alter clinical management. Screening for constitutional *MLH1* methylation is warranted in patients with early-onset EC or synchronous/metachronous tumors (any age) displaying *MLH1* methylation.

© 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

About 30% of endometrial cancers (EC) are mismatch repair (MMR) deficient (MMRd), detected by absence of immunoexpression of one or more MMR proteins [1], microsatellite instability (MSI) [2], or high mutational burden [3]. About 70% of MMRd EC are associated with aberrant methylation of the *MLH1* CpG island promoter, causing transcriptional silencing [4]. These cases are considered “sporadic” since tumor *MLH1* methylation is typically somatic-in-origin [5,6]. About 20% of MMRd EC are associated with Lynch syndrome (LS), caused by a germline pathogenic variant (PV) affecting a MMR gene (*MSH2*, *MLH1*, *MSH6*, *PMS2*) [7]. LS-associated cancer risks vary by gene mutated and sex, although EC in females and colorectal cancer (CRC) in both sexes are most prevalent. Lifelong surveillance, including regular colonoscopies, is recommended for early cancer detection and prevention [8].

Constitutional *MLH1* epimutation is an alternative mechanism that predisposes to MMRd cancers. This defect manifests as methylation of a single allele of the *MLH1* promoter throughout normal tissues, accompanied by transcriptional silencing of the methylated allele [9]. This serves as the “first-hit” to produce tumors displaying MSI, dual absence of *MLH1*/*PMS2* immunoexpression, and *MLH1* methylation [9,10]. Carriers of constitutional *MLH1* epimutation have presented with early-onset and/or multiple cancers akin to the *MLH1*-LS phenotype and about one-third of female carriers developed EC <60 years of age [11]. Familial cases of constitutional *MLH1* epimutation have been reported to show either autosomal dominant inheritance of *MLH1* methylation linked to a genetic variant within or nearby *MLH1*, or non-Mendelian inheritance in the absence of any apparent genetic variant [12–23]. However, most cases have no significant family history due to de novo occurrence of the constitutional *MLH1* epimutation, and negative germline genetic tests [9,22,24,25]. Therefore, cases with constitutional *MLH1* epimutation present a clinical and molecular diagnostic challenge. These cases need to be distinguished from common “sporadic” cases with somatic-in-origin tumor *MLH1* methylation, and diagnosed at first presentation of cancer, in order to receive appropriate genetic counseling and surveillance to prevent metachronous cancers that they are at high risk for. Additional testing for the presence of *MLH1* methylation in peripheral blood leukocytes (PBL), or other source of germline DNA, is required for a molecular diagnosis. This in turn, requires recognition of patients warranting this additional testing.

“Universal screening” of all EC for MMRd is recommended as the standard-of-care to guide precision therapy and identify cases warranting germline testing for LS. Current algorithms involve stepwise testing of all incident EC for MMRd by immunohistochemistry (IHC) of the MMR proteins (or MSI testing if results are uninterpretable) in the first tier. Reflex testing of those exhibiting dual loss of *MLH1*/*PMS2* (or MSI) for *MLH1* methylation is performed to identify “sporadic” cases for exclusion from genetic testing for LS [4,26–28]. According to current National Comprehensive Cancer Network (NCCN) guidelines for uterine neoplasms, MMRd EC cases that are unmethylated at *MLH1* are eligible

for LS testing, whilst no further testing is recommended for those whose tumor is *MLH1*-methylated [29]. NCCN guidelines for genetic/familial high risk assessment for CRC state that presence of tumor *MLH1* methylation can be used to exclude genetically high-risk cases and that constitutional *MLH1* methylation etiology is rare, but should be considered in cases with *MLH1*-methylated CRC or EC if early-onset (<50 years) or there is a family history [30]. In practice, universal screening may overlook cases whose *MLH1* methylation was constitutional (under the presumption it was somatic-in-origin). This may be compounded by the frequent lack of a family history in carriers of constitutional *MLH1* methylation, who may therefore, be misdiagnosed as a common sporadic case.

While constitutional *MLH1* epimutation is rare, its frequency among incident MMRd cancers remains unclear. Prior screens have focused on CRC cases, which have found the prevalence among patients meeting the revised Bethesda Guidelines for MSI testing with an *MLH1*-deficient tumor, and negative germline genetic test result, to be 3–9% [9,17,22,31–35]. Slightly higher frequencies have been reported with the inclusion of tumor *MLH1* methylation as a selection feature, at 3.5–15.6% [35–38]. However, only one screen for constitutional *MLH1* methylation in EC has been reported, conducted in a hospital-based unselected, consecutive series of EC cases in Japan, which identified 1/206 (0.49%) [39]. The patient had a prior colon cancer and a family history. MMR activity was not assessed systematically in this case series, so the overall rate of constitutional *MLH1* epimutation among MMRd cases could not be determined. To our knowledge, the frequency of constitutional *MLH1* epimutation among incident EC cases with *MLH1*-methylated tumors identified through universal screening has not previously been evaluated. Evidence-based guidelines are needed to select EC patients warranting screening for constitutional *MLH1* methylation.


We assessed the role of constitutional *MLH1* epimutation in patients ascertained via cancer clinics who had presented with *MLH1*-methylated EC <60 years. To estimate the frequency and age distribution of constitutional *MLH1* methylation among incident MMRd EC cases whose tumor was *MLH1*-methylated, we leveraged the clinical resources and prior molecular pathology findings from population-based EC cohorts in the “Columbus-area HNPCC Study” (Columbus) and the “Ohio Colorectal Cancer Prevention Initiative” (OCCPI), from Ohio, USA.

## 2. Materials and methods

The overall study design is shown in Fig. 1.

### 2.1. Cancer clinic-based ascertainment and sampling

Patients with MMRd, *MLH1*-methylated EC <60 years were referred by their treating physician or genetic counselor from cancer clinics in the USA (Fig. 1A). First-degree relatives of probands with constitutional *MLH1* epimutation were eligible to assess carrier status and potential inheritance. This study was approved by the Cedars-Sinai Medical Center



**Fig. 1.** Schematic of overall study design and assays for constitutional *MLH1* methylation analyses.

**A:** Flow diagram showing the ascertainment, selection, and numbers of patients eligible for testing for constitutional *MLH1* epimutation. **B:** Map of the *MLH1* CpG island proximal promoter region that corresponds with transcriptional activity, [6,43] and assays designed to interrogate methylation status and levels in bisulfite-converted genomic DNA (not to scale). Purple asterisk (\*) indicates the quantitative CpG pyrosequencing and high-sensitivity real-time methylation-specific PCR (qMSP) assays used for first-pass screening to detect constitutional *MLH1* methylation. Assays shown in gray are unbiased with respect to methylation status, such that PCR amplification will occur from both unmethylated and methylated templates. Assays in black are methylation-specific PCR-based (MSP) with primers overlapping designated CpG sites, hence amplification will occur only from methylated templates with high sensitivity. The MSP1 assay used for bisulfite-sequencing uses the same primers as the qMSP assay used for screening. MSP2 and MSP3 were used to confirm the presence of low-level methylation. Additional assays shown were used for confirmation of methylation. Horizontal bars show PCR products, circles show CpG sites interrogated within each amplicon. Orange line and squares indicate the location of the promoter c.-93G > A SNP (rs1800734) used to trace allele specificity for methylation in heterozygous cases positive for constitutional *MLH1* methylation. The unbiased clonal bisulfite-sequencing assay was used to confirm and identify allelic methylation in germline DNA in patients with high levels of methylation measured by CpG pyrosequencing, and in tumor DNA. MSP3 was used to determine allelic methylation in heterozygous cases with low-level methylation. Locations of each assay are numbered with respect to the translation start site at +1 of *MLH1* transcript, GenBank accession number NM\_000249.3.

institutional review board (Pro00049624) and subjects provided informed consent.

If PBL DNA was not already available, fresh samples were collected during a clinical appointment. Blood was collected into STRECK tubes and at least one additional non-circulating sample was requested, including saliva using Oragene-500 DNA Saliva Kit (DNA Genotek), buccal swab using DNA/RNA Shield Collection Kit (Zymo Research), or hair

follicles. Buffy coat was separated by standard centrifugation and PBL nuclei isolated before DNA extraction using the Blood and Cell Culture DNA Mini kit (Qiagen). DNA was extracted from saliva and buccal mucosa post nuclease deactivation using the PT-L2P kit (DNA Genotek), and from hair follicles using the QuickExtract DNA Solution (Lucigen), according to the manufacturers' instructions. Formalin-fixed paraffin-embedded (FFPE) tissue samples were macrodissected from 10  $\mu$ m

sections with reference to a hematoxylin and eosin-stained slide, following review and demarcation of areas of high tumor cellularity and normal cells by a pathologist. FFPE tissues were deparaffinized then DNA extracted using the QIAmp DNA FFPE Tissue Kit (Qiagen).

## 2.2. Population-based ascertainment

The first series of incident EC cases were derived from the Columbus cohort, which recruited unselected EC patients ( $n = 543$ ) who underwent surgery in a metropolitan hospital in the Columbus-area between 1999 and 2004 [40,41]. The second series was derived from the OCCPI cohort, which recruited unselected EC ( $n = 342$ ) patients who underwent surgery at Ohio State University between 2013 and 2016 [38]. As previously described, MMR status was determined by IHC of the MMR proteins and/or MSI assessment using the NCI-designated pentaplex panel, whereby instability at 2/5 markers was classified MSI-high, 1/5 was MSI-low, and 0/5 was microsatellite stable (MSS) [40]. *MLH1* methylation status in tumors showing loss of *MLH1* and/or MSI was previously assessed using established assays; methylation-specific PCR (MSP) (Columbus) [42,43], or CpG pyrosequencing (OCCPI) [44]. Eligibility criteria for inclusion in this study were cases whose tumor showed (1) IHC loss of *MLH1*, or MSI-high if IHC data was missing, and (2) *MLH1* methylation, and (3) available genomic DNA from PBL (Columbus) or whole blood (OCCPI) (Fig. 1A). Patient specimens and data were deidentified.

## 2.3. Screen for constitutional *MLH1* methylation

Bisulfite-conversion was performed on 500 ng DNA using the EZ DNA Methylation Gold Kit (Zymo Research) and ~ 50 ng input into each assay. First-pass screening for constitutional *MLH1* methylation was performed using two assays previously described for this purpose (Fig. 1B), namely quantitative CpG pyrosequencing [25], and high-sensitivity real-time methylation-specific PCR (qMSP) [12,18]. Samples were considered methylation-positive by pyrosequencing if all five CpG sites interrogated yielded a value  $\geq 1$  and the mean methylation was 2.3% (limit of detection) or above (Supplementary Figs. 1, 2). QMSP was performed on the CFX96 Thermal Cycler (Bio-Rad) using SYBR-Green fluorescein, followed by melt analysis to ensure methylation-specificity of the *MLH1* amplicon, alongside *MYOD* as a control for sample input (Supplementary Fig. 3). A semi-quantitative percentage of methylated reference (PMR) value was calculated with reference to a fully-methylated sample (Universal Methylated DNA Standard, Zymo Research), as previously described [45]. This qMSP enables the detection of low-level mosaicism and samples were considered positive if the PMR was 0.1% (limit of detection) or above (Supplementary Fig. 4). Both assays were applied to all genomic DNA samples. A follow-up assay, based on direct or clonal bisulfite-sequencing, was performed in one or more tissue samples from methylation-positive patients to confirm the presence of constitutional *MLH1* methylation and to determine allelic methylation patterns in patients heterozygous for the common c.-93G > A (rs1800734) promoter SNP (Fig. 1B). The assay selected depended on initial methylation levels detected and c.-93G > A zygosity (Fig. 1B). Methodological details are provided in Supplementary Methods.

To screen for epimutation-associated genetic variants and promoter SNP genotyping, Sanger sequencing across the *MLH1* CpG island was performed in cases with constitutional *MLH1* methylation detected, as previously described [12,18].

## 3. Results

### 3.1. Clinically-ascertained patients

Patients ascertained via cancer clinics were eligible for inclusion if they had presented with EC <60 years and their tumor displayed MMRd (loss of *MLH1* expression by IHC, and/or MSI) and *MLH1*


methylation. Four patients met these inclusion criteria and constitutional *MLH1* methylation was detected in three, as follows:

Patient 192, of Native American ancestry, was diagnosed at 57 years with EC, FIGO stage IA (T1a, Nx), histologic grade (G) 1 and cervical clear cell adenocarcinoma, FIGO stage 1A2 (1a2, Nx). There was a wide margin between the two tumors and immunophenotyping of the cervical tumor was consistent with a diagnosis of clear cell adenocarcinoma as a distinct primary cancer (positivity for PAX-8, HNF-1B, CKAE1/AE3, CK7, wildtype TP53, patchy P16, and negativity for ER, PR, Napsin-A, CEA, CK5, P40, CDX2, CK20, OCT3, GATA-3, SOX-10, and CA-IX). MSI testing only was conducted on the EC, which was MSI-high. *MLH1* methylation testing was performed simultaneously on the EC and uninvolved tissue and both were methylation positive. Follow-up testing for constitutional *MLH1* methylation in blood was recommended. The patient had a maternal family history that included LS-type cancers, however, age of onset among relatives and paternal history were unknown (Fig. 2A). PBL nuclei and saliva tested positive for *MLH1* methylation by qMSP (Fig. 2B), and pyrosequencing measured methylation levels at 47–48% (Fig. 2C). The patient was heterozygous at the c.-93G > A SNP (rs1800734) within the *MLH1* promoter and clonal bisulfite-sequencing across the region encompassing this SNP showed monoallelic methylation specifically of the 'A' allele (Fig. 2D). No other sequence variants were identified within the *MLH1* CpG island. This molecular profile was consistent with a "classic" monoallelic constitutional *MLH1* epimutation.

Patient 213 is White and was diagnosed at 36 years with EC, FIGO stage IA (T1a, Nx), G1, which showed absence of *MLH1*/*PMS2* and *MLH1* methylation. On this basis, no further follow-up was considered necessary at that time. At 41 years, she presented with a poorly differentiated colon (cecum) adenocarcinoma, AJCC stage IIIC (T3, N2b, Mx). Molecular pathology revealed loss of *MLH1*/*PMS2*, *MLH1* methylation, and absence of the somatic *BRAF*<sup>V600E</sup> mutation that is frequently associated with somatic-in-origin *MLH1* methylation in sporadic MMRd CRC [46,47]. Given her personal history of *MLH1*-methylated metachronous cancers, she was referred for blood-based constitutional *MLH1* methylation testing in a CLIA-approved facility (Mayo Clinic) and received a positive result. Patient 213 and her parents joined our study to confirm/determine carrier status and potential inheritance. The mother had no personal history of cancer. The father had prior non-LS cancer diagnoses (Fig. 3A). The nuclear trio each provided fresh samples of blood, saliva, and buccal mucosa. *MLH1* methylation testing was consistently positive in Patient 213 by qMSP (Fig. 3B), and pyrosequencing measured ~50% methylation (Fig. 3C). Clonal bisulfite-sequencing confirmed hemiallelic methylation (Fig. 3D), however, the patient was homozygous across the *MLH1* promoter, so methylation could not be assigned to a particular genetic or parental allele. Both parents were unmethylated in all tissues tested (Fig. 3E, F). No sequence variants were identified within the *MLH1* CpG island in this nuclear family. This was consistent with a "classic" hemiallelic constitutional *MLH1* epimutation, which arose de novo in the proband with no apparent genetic basis.


Patient 177 is White and presented with EC (FIGO stage 1B, G1) at 59 years, with *MLH1*/*PMS2* loss and *MLH1* methylation. At 61 years, she presented with metastatic colon cancer, which was MMR-proficient by IHC and *BRAF*<sup>V600E</sup> mutant. Her mother developed breast cancer at 35 years. Patient 177 was referred for germline genetic testing (Ambry Genetics 36-gene CancerNext panel) and was negative. PBL DNA tested negative for constitutional *MLH1* methylation (Supplementary Fig. 5).

Patient 166 is White and presented with multiple primary cancers with no remarkable family history. She first presented with skin sebaceous carcinoma at 54 years, then synchronous endometrial and small intestine cancers at 55 years (Fig. 4A). Surgical pathology diagnosed EC, FIGO stage IIIC1 (T1a, N1, M0), G1, and small intestine adenocarcinoma, AJCC stage IIB (T4, N0, M0), as distinct primaries. All three cancers showed loss of *MLH1*/*PMS2*, and MSI testing of the EC and small




**Fig. 2.** Detection of monoallelic constitutional *MLH1* epimutation in Proband 192.

A: Maternal pedigree of Patient 192. EC, endometrial cancer; CRC, colorectal cancer; unk, unknown. For privacy, members of younger generations are not included (none have had a cancer diagnosis). B: Real-time methylation-specific PCR (qMSP) was performed from c.-188 to c.-403 within the *MLH1* promoter on bisulfite-converted genomic DNA from the nuclei of peripheral blood leukocytes (PBL) and saliva. Amplification curves show methylated *MLH1* (red), which amplifies only when methylated DNA is present, run in parallel with *MYOD* (blue), which serves as a quality control measure for sample input and integrity. The percentage of methylated reference (PMR) value is shown. The high-resolution melt curve of the *MLH1* amplicon for each sample indicates specificity for methylated amplicons with melt peak at  $76 \pm 0.5$  °C. C: Pyrosequencing traces are shown for five CpG sites from c.-241 to c.-272 of the *MLH1* promoter in bisulfite-converted genomic DNA from PBL nuclei and saliva. Methylation is detected by the presence of a peak at the cytosine (C) within each CpG site interrogated (gray bars), whereas unmethylated cytosines are detected as thymine (T) peaks within the same CpG sites, due to the conversion of unmethylated cytosines to uracils using bisulfite treatment. The assay measures the relative levels of methylated C against unmethylated cytosines at each CpG site interrogated, and reports these as a percentage of methylation value above. The mean level of methylation across all five CpG sites is calculated and shown above. The yellow bar indicates a non-CpG cytosine used as a quality control measure to ensure complete bisulfite-conversion to T, whereupon this yields a valid test result. Methylation was measured at 48.2% in PBL and 47.4% in saliva. D: Left, Sanger sequencing electropherogram showing Patient 192 was heterozygous for the *MLH1* promoter c.-93G > A SNP (rs1800734). Right, pictogram of clonal bisulfite sequencing across a fragment of the *MLH1* CpG island promoter region from c.-48 to c.-370 showing the methylation status at 16 individual CpG sites (circles) within individual alleles (horizontal lines). The rs1800734 SNP genotypes are represented by colored squares on each allele. This SNP is flanked by CpG dinucleotides numbered correspondingly in the electropherogram (left) and pictogram (right). Hypermethylation was restricted to alleles bearing the 'A' genotype at rs1800734, indicating monoallelic methylation.



**Fig. 3.** Detection of hemiallelic constitutional *MLH1* epimutation in EC Proband 213.

A: Nuclear pedigree of patient 213, showing a non-Lynch syndrome cancer history on the paternal side. B: Left, illustrative amplification curves showing positive amplification of methylated *MLH1* by real-time methylation-specific PCR (qMSP) within the *MLH1* promoter on bisulfite-converted genomic DNA. Right, melt curve of the amplicons, confirms product specificity at a melt temperature of  $76 \pm 0.5$  °C. C: CpG pyrosequencing traces with legend according to Fig. 2. *MLH1* methylation measured between 46.8% to 52.4%. D: Clonal bisulfite sequencing of a larger fragment of the *MLH1* promoter confirms the presence of methylation in a hemiallelic pattern, consistent with the CpG pyrosequencing result. The patient was homozygous “G” at the rs1800734 SNP, so the parental allele-of-origin of the constitutional *MLH1* methylation could not be determined. E: Illustrative CpG pyrosequencing results for the parents. F: Illustrative qMSP results for the parents. Both parents were negative for constitutional *MLH1* methylation in all tests. PBL, peripheral blood leukocytes.



**Fig. 4.** Detection of low-level constitutional *MLH1* methylation mosaicism in Patient 166.

A: CpG pyrosequencing yields negative test results in genomic DNA from peripheral blood leukocytes (PBL) nuclei and saliva, but low levels of methylation are detectable in DNA extracted from other sources of histologically normal tissue samples (macrodissected formalin-fixed paraffin-embedded) from surgically resected organs, as labeled. B: Real-time methylation-specific PCR (qMSP) shows positive amplification of methylated *MLH1* templates in PBL and saliva samples with methylation levels too low to be detectable by CpG pyrosequencing, but absence of methylation in hair follicles. C: Top, partial sequence within the *MLH1* promoter shows heterozygosity for the c.-93G > A SNP (arrow). Dashed lines show the locations of individual CpG sites flanking the SNP. Beneath, Sanger sequencing of methylation-specific PCR (MSP) products across the same region encompassing the c.-93G > A SNP site after bisulfite-conversion of genomic DNA shows only methylated templates were amplified and these amplicons only contained the G genotype at the c.-93 SNP position. This indicates the low-level methylation (amplifiable by MSP) is linked to the G allele.

intestine tumors showed both were MSI-high. *MLH1* methylation testing was performed on the EC, then retrospectively on the sebaceous carcinoma, and both were methylated. Germline genetic testing on Ambry Genetics ColoNext 20-gene panel was negative. Patient 166 provided fresh samples of blood, saliva, and hair follicles. Tumor and accompanying normal FFPE tissue blocks were retrieved. *MLH1* methylation testing revealed widespread mosaicism in normal tissues. *MLH1* methylation levels were too low in PBL nuclei and saliva to detect by pyrosequencing (Fig. 4A), but were both positive by more sensitive qMSP with PMR values of 1.0% (Fig. 4B). Hair follicles had no detectable methylation, even by qMSP (Fig. 4B). Other histologically normal (resected) tissues showed low-level *MLH1* methylation measurable by pyrosequencing, ranging from 2.4% in small intestinal epithelium to 7.6% in uterine epithelium (Fig. 4A). Patient 166 was heterozygous for the c.-93G > A promoter SNP. MSP across this SNP followed by direct sequencing of the amplicon revealed the low-level methylation to be monoallelic, linked to the G allele in all normal tissues tested (Fig. 4C). To determine if methylation of the “G” allele in such a small proportion of normal cells (~5–15%) had predisposed to the development of multiple primary tumors, we performed extended testing in each tumor to identify potential “second hits” affecting the unmethylated “A” allele. We first measured significant levels of *MLH1* methylation in all three tumors by pyrosequencing (Fig. 5A). Next, clonal bisulfite-sequencing (Fig. 5B), and promoter sequencing (Fig. 5C), across the c.-93G > A SNP site in each tumor was performed to trace allelic methylation patterns and detect potential loss-of-heterozygosity (LOH), respectively, with reference to paired normal tissues. The sebaceous carcinoma showed both LOH of the ‘A’ allele, as well as methylation of both the (constitutionally-methylated) G alleles and the remnant A alleles (two second-hits). The EC showed monoallelic methylation of the ‘G’ alleles plus LOH of the ‘A’ allele. The small intestine adenocarcinoma showed methylation of both alleles with retention-of-heterozygosity, indicating somatic methylation of the A allele was the second-hit in this tumor. Collectively, these findings are consistent with constitutional *MLH1* methylation of the G allele in a proportion of cells serving as the “first hit”, followed by a somatic second hit affecting the A allele in the development of all three cancers.

### 3.2. Population-based ascertainment

To determine the frequency of constitutional *MLH1* methylation among incident EC cases whose tumor was identified as MMRd and *MLH1*-methylated upon universal screening, we performed a nested retrospective study of EC cases selected by this tumor feature in population-based cohorts (Fig. 1A).

**Columbus cohort:** Of 543 unselected EC cases, 85 (15.1%) were eligible for inclusion based on IHC loss of *MLH1* expression and/or MSI and *MLH1* methylation in their tumor, irrespective of age, prior cancer, family history, or prior genetic testing (Fig. 1A). PBL DNA was available for 74 cases, median age 64.0 years (range 38–88 years). Of these, 64 tumors (86.5%) were MSI-high, seven MSI-low, and three MSS. Methylation testing in PBL DNA was successful for 68 cases. Test failures did not significantly alter the distribution in age or frequency of MSI within the selected series. All 68 EC cases were negative for constitutional *MLH1* methylation, among whom 21 were < 60 years and two were < 50 years (Fig. 1C).

**OCCPI cohort:** Given the negative findings in the Columbus cohort and to boost the sample size among younger cases, we limited screening of the OCCPI cohort to EC cases <60 years. Twenty-four, age range 36–59 years, with *MLH1* loss and *MLH1* methylation in their tumor were included, of which 17 were MSI-high, five MSI-low, and two were MSS. All 24 cases tested negative for *MLH1* methylation in whole blood DNA by pyrosequencing, however, low-level *MLH1* methylation was detected by qMSP in one patient (4%). Patient EC-32 had a qMSP PMR value of 0.17%, below the pyrosequencing detection threshold

(Fig. 6A, B). EC-32 was diagnosed with EC (FIGO stage IIIC1), at 36 years and had no family history. To confirm the qMSP methylation-positive signal, we performed conventional (non-fluorescent) MSP in two distinct regions of the *MLH1* CpG island (Fig. 1B), followed by clonal bisulfite-sequencing of the amplicons. Both confirmed the presence of methylation in blood DNA (Fig. 6C). No genetic variants were identified in the *MLH1* CpG island.

Since methylation testing in the OCCPI cohort was performed in whole blood DNA, we were cognizant that high-sensitivity qMSP could have detected contaminating circulating tumor DNA (ctDNA) within plasma. However, the blood sample tested was drawn three months post-operatively, therefore, the methylation-positive signal was unlikely generated by ctDNA shed by the primary tumor, although residual disease was possible. Therefore, we tested uninvolved endometrial tissue as an additional source of normal tissue, which was positive for *MLH1* methylation both by qMSP with a PMR value of 1.1% and by pyrosequencing at 2.8% (Fig. 6A, B). Thus, *MLH1* methylation in the tissue-of-origin was slightly higher than in blood. These findings are consistent with Patient EC-32 having low-level mosaicism for constitutional *MLH1* methylation, which predisposed to her early-onset EC displaying high-level *MLH1* methylation (Fig. 6B).


## 4. Discussion

Key goals of universal screening of all incident EC (and CRC) for MMRd and LS are to identify patients genetically at high-risk who would benefit from enrollment in life-long cancer surveillance programs and to extend cascade genetic testing to blood relatives. However, current algorithms that utilize tumor *MLH1* methylation testing to rule out hereditary risk may result in rare cases with constitutional *MLH1* epimutation being misdiagnosed as common sporadic cases. Poor recognition of this mechanism and inconsistent guidelines may result in failure to correctly diagnose it, missing the opportunity to enroll these patients in risk-appropriate surveillance. Consensus, evidence-based guidelines for appropriate triaging of EC patients warranting testing for constitutional *MLH1* methylation are needed. Given tumor *MLH1* methylation testing is an integral component of the molecular pathology-based algorithm for LS recognition, we aimed to determine the role and frequency of constitutional *MLH1* epimutation among patients presenting with *MLH1*-methylated EC.


Among four index patients referred to our study by a cancer clinic, three (Patients 192, 213, and 166) had constitutional *MLH1* methylation. Two (Patients 192 and 213) with mono/hemiallelic epimutation had presented with *MLH1*-methylated EC as their first or dual-first cancer. Notably, the impetus for referring both Patients 192 and 213 for constitutional *MLH1* methylation work-up was not based solely on their initial cancer diagnosis or tumor molecular pathology features. In the case of Patient 192, diagnosed with EC at 57 years, an unspecified sample of resected normal tissue from her TH/BSO had been tested for *MLH1* methylation alongside her tumor and both were positive. Serendipitous detection of *MLH1* methylation in a normal tissue had prompted the recommendation for follow-up blood-based testing. Parallel testing of uninvolved normal tissue alongside the tumor during routine molecular pathology in early-onset cases could provide a feasible route for the detection of constitutional *MLH1* epimutation. In the case of Patient 213, who initially presented with *MLH1*-methylated EC at 36 years, unfortunately testing for constitutional *MLH1* epimutation was not considered until she presented five years later with locally-advanced colon cancer that also displayed *MLH1* methylation. A correct molecular diagnosis after her first presentation with EC would have significantly altered her clinical management thereafter.

Patients 166 and OCCPI EC-32 both had low-level mosaic methylation and yet presented either with multiple *MLH1*-methylated primaries (Patient 166), or EC as the first-presenting cancer at the young age of 36 years (EC-32). In both patients, low-level methylation was





**Fig. 5.** Low-level mosaic constitutional *MLH1* methylation predisposes to multiple *MLH1*-methylated primary tumors in Patient 166. A: CpG pyrosequencing confirms the presence of significant levels of *MLH1* methylation in all three primary tumors, including the small intestine adenocarcinoma, which had not previously been assessed for this. B: Clonal bisulfite sequencing within the *MLH1* promoter encompassing the c.-93G > A SNP (rs1800734) using primers unbiased with respect to methylation status shows the patterns of methylation in the tumors (left). The skin sebaceous carcinoma and small intestine tumors had methylation on both alleles, although few A alleles at c.-93 remained in the skin tumor. The EC was monoallelically methylated on the G allele. The same assay performed on accompanying normal tissue samples (right) only detected a single methylated molecule in endometrial epithelium, which was the G allele at c.-93G > A. C: The c.-93G > A SNP was used to trace allelic representation in each primary cancer (right) with reference to a paired normal tissue sample (right). Partial Sanger sequences are shown across the c.-93G > A SNP, with measurements of each allele in relative fluorescence units (RFU) taken from the peak for each genotype shown below. Loss-of-heterozygosity (LOH) was assessed by calculating  $(A/G_{\text{Tumor}})/(A/G_{\text{Normal}})$ . If A/G was  $\leq 0.6$  in the tumor, this was designated as LOH of the A allele. Retention of heterozygosity (ROH) was designated if A/G > 0.6 in the tumor.



**Fig. 6.** Detection of low-level constitutional *MLH1* methylation in OCCPI patient EC-32.

A: CpG pyrosequencing traces are shown for DNA from whole blood, uninvolved endometrial tissue, and tumor, as labeled. The mean methylation value is shown above. Methylation was undetectable in whole blood DNA, given this was below the limit of detection (2.3%), but was detectable at low levels (2.8%) in uninvolved normal endometrial tissue and at high levels (65.6%) in the tumor. B: Real-time methylation-specific PCR (qMSP) within the *MLH1* promoter on bisulfite-converted genomic DNA from whole blood (left) and confirmed in uninvolved normal endometrial tissue (right). Amplification curves show methylated *MLH1* (red), which amplifies only when methylated genomic DNA template is present, run in parallel with *MYOD* (blue), which serves as a quality control measure for sample input and integrity. High resolution melt curves of the *MLH1* amplicons are shown, indicating specificity for methylated amplicons with melt peaks at  $76 \pm 0.5$  °C. C: Electrophoresis gels of traditional *MLH1* methylation-specific PCR (MSP) amplification products according to Fig. 1. Left, MSP1 used the same primers as the qMSP. Right, MSP2 was conducted in a distinct region of the *MLH1* CpG island. Both MSP reactions included DNA from whole blood (WB) of EC-32, a healthy control (HC, negative control), RKO colorectal cancer cell line (positive control), and a reaction with no template (NT) added. Beneath, pictograms of clonal bisulfite sequencing of each MSP amplicon show the methylation status at 16 individual CpG sites within the respective regions. Black circles show methylated CpG sites and white circles show unmethylated CpG sites on individual molecules (horizontal line).

confirmed in two or more normal tissue types. In Patient 166, we unraveled clear evidence of the role for low-level, monoallelic methylation in a fraction of cells in predisposing to the development of all three tumors via somatic methylation and/or LOH of the unaffected allele. These two patients illustrate that low-level mosaic constitutional *MLH1* methylation can nevertheless confer high risks for LS-type cancers.

To determine if screening for constitutional *MLH1* epimutation might be warranted among EC cases identified via universal screening to have *MLH1*-methylated tumors, we determined the frequency of constitutional *MLH1* methylation in retrospective nested studies of population-based cohorts of incidental EC. In the Columbus cohort, EC cases were selected solely based on the tumor molecular features of MMRd and *MLH1* methylation, therefore this study was unbiased with respect to age at cancer diagnosis, prior cancer, genetic testing, or family history. Yet, given the negative findings in this cohort, and the small sample size among younger cases, we limited our subsequent study of the OCCPI cohort to EC patients diagnosed <60 years with the same tumor features. By combining the two cohorts, the rate of constitutional *MLH1* methylation among incident *MLH1*-methylated EC cases overall (all ages) was negligible (0–1%) and the rate among cases aged <60 years was 2% (Columbus 0/21, OCCPI 1/24). However, the positive detection rate for constitutional *MLH1* methylation in *MLH1*-methylated EC cases <50 years was 1/6 (17%) in the combined cohorts. If consideration for screening for constitutional *MLH1* methylation were limited to cases <50 years of age, only a small proportion of patients with *MLH1*-methylated tumors overall would warrant testing, rendering this feasible and potentially high-yield. However, limiting screening by age < 50 years would miss cases such as Patients 192 and 166, who presented with EC in their fifties.

A key limitation of this second aspect of our study was the small sample size among younger patients, despite their derivation from large population-based series. However, these small case numbers also serve to illustrate that screening among early-onset *MLH1*-methylated EC cases would be minimal. The rarity of constitutional *MLH1* epimutation among incident EC cases with *MLH1*-methylated tumors overall is unsurprising, given *MLH1* methylation is typically somatic-in-origin and accounts for the significant proportion of MMRd EC. However, the finding of constitutional *MLH1* epimutation in one patient with incident *MLH1*-methylated EC out of six (~17%) <50 years, or out of 45 (~2%) <60 years in the combined Ohio cohorts, is non-trivial. Furthermore, EC was the “sentinel” cancer in two clinic-based cases (192 and 213) and EC-32. Based on our findings, we proffer that routine screening for constitutional *MLH1* methylation is warranted for incident EC cases <50 years whose tumor is *MLH1*-methylated, as well as patients presenting with synchronous or metachronous LS-type cancers with *MLH1*-methylation at any age, irrespective of family history or whether prior genetic testing has been completed. Further consideration should also be given to parallel testing for *MLH1* methylation in a normal tissue sample from surgical resection specimens in early-onset cases. Gynecologic oncologists, pathologists, and genetic counselors play critical and coordinated roles in identifying patients at high genetic risk for cancer and should also consider referral for constitutional *MLH1* epimutation testing in patients displaying these clinical and molecular pathology features.

#### Author contributions

Conceptualization: MPH, HH, RP.  
 Methodology: MPH, RA.  
 Data generation and analyses: MPH, RA, LZ, FA, ED, JJ-LW, XY, SR, DS, TC, RB, TD, DG, RP, HH.  
 Data curation: MPH, RA, LZ, FA, HH, RP.  
 Statistical analyses: JJ-LW, MPH.  
 Results interpretation: MPH, RA, FA, ED, JJ-LW, XY, SR, DS, TC, RB, TD, MP, GC, HH, RP.

Writing - original draft: MPH  
 Writing - review & editing: All authors.  
 Funding acquisition: MPH, HH, GC, MP.

#### Declaration of Competing Interest

The authors have no conflicts of interest to declare.

#### Acknowledgements

This study was funded by the USA National Institutes of Health/National Cancer Institute R01 grants CA218342 (Megan Hitchins), and CA67941 and CA16058 (Heather Hampel); a Cedars-Sinai Medical Center Precision Health Initiative Award (Megan Hitchins); Spanish Ministry of Science grant SAF2015-68016-R (Gabriel Capellá), PID2019-111254RB-I00 (Gabriel Capellá and Marta Pineda); Travel Fellowships awarded to Estela Damaso from the Spanish Ministry of Economy, Industry and Competitiveness (MINECO, EEBB-I-16-11581) and the RTICC network (RD12/0036/0031).

#### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ygyno.2023.02.017>.

#### References

- [1] R. Parsons, G.M. Li, M.J. Longley, et al., Hypermutability and mismatch repair deficiency in RER+ tumor cells, *Cell* 75 (6) (1993) 1227–1236.
- [2] C.R. Boland, S.N. Thibodeau, S.R. Hamilton, et al., A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer, *Cancer Res.* 58 (22) (1998) 5248–5257.
- [3] H. Yamamoto, K. Imai, An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine, *Semin. Oncol.* 46 (3) (2019) 261–270.
- [4] P.J. Goodfellow, C.C. Billingsley, H.A. Lankes, et al., Combined microsatellite instability, *MLH1* methylation analysis, and immunohistochemistry for Lynch syndrome screening in endometrial cancers from GOG210: an NRG oncology and gynecologic oncology group study, *J. Clin. Oncol.* 33 (36) (2015) 4301–4308.
- [5] M. Esteller, L. Catusus, X. Matias-Guiu, et al., hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis, *Am. J. Pathol.* 155 (5) (1999) 1767–1772.
- [6] G. Deng, E. Peng, J. Gum, et al., Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer, *Br. J. Cancer* 86 (4) (2002) 574–579.
- [7] P. Peltomaki, Update on Lynch syndrome genomics, *Familial Cancer* 15 (3) (2016) 385–393.
- [8] H.T. Lynch, C.L. Snyder, T.G. Shaw, et al., Milestones of Lynch syndrome: 1895–2015, *Nat. Rev. Cancer* 15 (3) (2015) 181–194.
- [9] M. Hitchins, R. Williams, K. Cheong, et al., *MLH1* germline epimutations as a factor in hereditary nonpolyposis colorectal cancer, *Gastroenterology*. 129 (5) (2005) 1392–1399.
- [10] I. Gazzoli, M. Loda, J. Garber, et al., A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the *MLH1* gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor, *Cancer Res.* 62 (14) (2002) 3925–3928.
- [11] M.P. Hitchins, The role of epigenetics in Lynch syndrome, *Familial Cancer* 12 (2) (2013) 189–205.
- [12] M.P. Hitchins, R.W. Rapkins, C.T. Kwok, et al., Dominantly inherited constitutional epigenetic silencing of *MLH1* in a cancer-affected family is linked to a single nucleotide variant within the 5'UTR, *Cancer Cell* 20 (2) (2011) 200–213.
- [13] C.T. Kwok, I.P. Vogelaar, W.A. van Zelst-Stams, et al., The *MLH1* c.-27C>a and c.85G>T variants are linked to dominantly inherited *MLH1* epimutation and are borne on a European ancestral haplotype, *Eur. J. Hum. Genet.* 22 (5) (2014) 617–624.
- [14] J. Leclerc, C. Flament, T. Lovecchio, et al., Diversity of genetic events associated with *MLH1* promoter methylation in Lynch syndrome families with heritable constitutional epimutation, *Genet. Med.* 20 (12) (2018) 1589–1599.
- [15] M. Morak, H.K. Schackert, N. Rahner, et al., Further evidence for heritability of an epimutation in one of 12 cases with *MLH1* promoter methylation in blood cells clinically displaying HNPCC, *Eur. J. Hum. Genet.* 16 (7) (2008) 804–811.
- [16] M. Morak, U. Koehler, H.K. Schackert, et al., Biallelic *MLH1* SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome, *J. Med. Genet.* 48 (8) (2011) 513–519.
- [17] A. Gylling, M. Ridanpaa, O. Vierimaa, et al., Large genomic rearrangements and germline epimutations in Lynch syndrome, *Int. J. Cancer* 124 (10) (2009) 2333–2340.

- [18] R.L. Ward, T. Dobbins, N.M. Lindor, et al., Identification of constitutional MLH1 epimutations and promoter variants in colorectal cancer patients from the Colon Cancer family registry, *Genet. Med.* 15 (1) (2013) 25–35.
- [19] G. Cini, I. Carnevali, M. Quaia, et al., Concomitant mutation and epimutation of the MLH1 gene in a Lynch syndrome family, *Carcinogenesis* 36 (4) (2015) 452–458.
- [20] M. Morak, A. Ibsler, G. Keller, et al., Comprehensive analysis of the MLH1 promoter region in 480 patients with colorectal cancer and 1150 controls reveals new variants including one with a heritable constitutional MLH1 epimutation, *J. Med. Genet.* 55 (4) (2018) 240–248.
- [21] M. Crepin, M.C. Dieu, S. Lejeune, et al., Evidence of constitutional MLH1 epimutation associated to transgenerational inheritance of cancer susceptibility, *Hum. Mutat.* 33 (1) (2012) 180–188.
- [22] M.P. Hitchins, J.J. Wong, G. Suthers, et al., Inheritance of a cancer-associated MLH1 germ-line epimutation, *N. Engl. J. Med.* 356 (7) (2007) 697–705.
- [23] M.A. Sloane, A.C. Nunez, D. Packham, et al., Mosaic epigenetic inheritance as a cause of early-onset colorectal Cancer, *JAMA Oncol.* 1 (7) (2015) 953–957.
- [24] M. Hitchins, S. Owens, C.T. Kwok, et al., Identification of new cases of early-onset colorectal cancer with an MLH1 epimutation in an ethnically diverse south African cohort (dagger), *Clin. Genet.* 80 (5) (2011) 428–434.
- [25] A. Goel, T.P. Nguyen, H.C. Leung, et al., De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one, *Int. J. Cancer* 128 (4) (2011) 869–878.
- [26] D.D. Buchanan, Y.Y. Tan, M.D. Walsh, et al., Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing, *J. Clin. Oncol.* 32 (2) (2014) 90–100.
- [27] B.A. Batte, A.S. Bruegl, M.S. Daniels, et al., Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome, *Gynecol. Oncol.* 134 (2) (2014) 319–325.
- [28] E. Stelloo, A.M.L. Jansen, E.M. Osse, et al., Practical guidance for mismatch repair-deficiency testing in endometrial cancer, *Ann. Oncol.* 28 (1) (2017) 96–102.
- [29] NCCN, NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms, 2021.
- [30] NCCN, Guidelines, Genetic/Familial High-Risk Assessment, Colorectal, 2022.
- [31] R.C. Niessen, R.M. Hofstra, H. Westers, et al., Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome, *Genes Chromosom. Cancer* 48 (8) (2009) 737–744.
- [32] L. Valle, P. Carbonell, V. Fernandez, et al., MLH1 germline epimutations in selected patients with early-onset non-polyposis colorectal cancer, *Clin. Genet.* 71 (3) (2007) 232–237.
- [33] M. Pineda, P. Mur, M.D. Iniesta, et al., MLH1 methylation screening is effective in identifying epimutation carriers, *Eur. J. Hum. Genet.* 20 (12) (2012) 1256–1264.
- [34] F. Crucianelli, R. Tricarico, D. Turchetti, et al., MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria, *Epigenetics* 9 (10) (2014) 1431–1438.
- [35] A. Castillejo, E. Hernandez-Illan, M. Rodriguez-Soler, et al., Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer, *J. Med. Genet.* 52 (7) (2015) 498–502.
- [36] E.H. van Roon, M. van Puijenbroek, A. Middeldorp, et al., Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? *BMC Cancer* 10 (2010) 180.
- [37] M. Pineda, P. Mur, M.D. Iniesta, et al., MLH1 methylation screening is effective in identifying epimutation carriers, *Eur. J. Hum. Genet.* 20 (12) (2012) 1256–1264.
- [38] R. Pearlman, W.L. Frankel, B.J. Swanson, et al., Prospective statewide study of universal screening for hereditary colorectal cancer: the Ohio colorectal cancer prevention initiative, *JCO Precis. Oncol.* (2021) 5.
- [39] T. Takeda, K. Banno, M. Yanokura, et al., Methylation analysis of DNA mismatch repair genes using DNA derived from the peripheral blood of patients with endometrial Cancer: Epimutation in endometrial carcinogenesis, *Genes (Basel)* 7 (10) (2016).
- [40] H. Hampel, W. Frankel, J. Panescu, et al., Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients, *Cancer Res.* 66 (15) (2006) 7810–7817.
- [41] H. Hampel, J. Panescu, J. Lockman, et al., Comment on: screening for Lynch syndrome (hereditary nonpolyposis colorectal Cancer) among endometrial Cancer patients, *Cancer Res.* 67 (19) (2007) 9603.
- [42] J.G. Herman, A. Umar, K. Polyak, et al., Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma, *Proc. Natl. Acad. Sci. U. S. A.* 95 (12) (1998) 6870–6875.
- [43] G. Deng, A. Chen, J. Hong, et al., Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression, *Cancer Res.* 59 (9) (1999) 2029–2033.
- [44] K. Newton, K. Green, F. Laloo, et al., Colonoscopy screening compliance and outcomes in patients with Lynch syndrome, *Color. Dis.* 17 (1) (2015) 38–46.
- [45] S. Ogino, T. Kawasaki, M. Brahmandam, et al., Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis, *J. Mol. Diagn.* 8 (2) (2006) 209–217.
- [46] A. McGivern, C.V. Wynter, V.L. Whitehall, et al., Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer, *Familial Cancer* 3 (2) (2004) 101–107.
- [47] G. Deng, I. Bell, S. Crawley, et al., BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer, *Clin. Cancer Res.* 10 (1 Pt 1) (2004) 191–195.